NovoCure NVCR Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $93.7M-37.4% | $87.53M-31.2% | $93.55M-42.9% | $342.12M+84.5% | $149.62M-9.2% | ||
| $42.22M+5.0% | $43.46M+10.1% | $41.11M+17.2% | $39.1M0.0% | $40.21M-0.6% | ||
| $638.52M-41.1% | $631.66M-42.0% | $646.73M-41.6% | $1.2B+9.5% | $1.08B-0.9% | ||
| $75.37M-6.2% | $76.28M-4.2% | $77.61M-0.1% | $79.98M+9.2% | $80.33M+20.8% | ||
| $156.67M-3.6% | $156.26M-2.0% | $157.6M+17.4% | $161.34M+27.3% | $162.58M+36.2% | ||
| $795.19M-36.2% | $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% | $1.25B+2.8% | ||
| $130.73M+26.1% | $127.24M+33.8% | $122.23M+16.3% | $118.92M+30.2% | $103.68M+15.0% | ||
| $220.71M-70.6% | $217.58M-70.7% | $223.23M-70.5% | $776.01M+5.6% | $749.63M+343% | ||
| $236.39M+61.0% | $239.63M+66.9% | $240.63M+93.7% | $243.86M+93.2% | $146.8M-78.5% | ||
| $457.1M-49.0% | $457.21M-48.4% | $463.86M-47.3% | $1.02B+18.4% | $896.43M+5.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$1.38B-12.1% | -$1.36B-14.6% | -$1.29B-11.8% | -$1.27B-16.3% | -$1.23B-16.2% | ||
| $338.09M-3.2% | $330.72M-8.6% | $340.47M-5.5% | $341.33M-5.4% | $349.44M-3.4% | ||
| $795.19M-36.2% | $787.93M-36.9% | $804.33M-35.2% | $1.36B+11.4% | $1.25B+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are NovoCure's total assets?
- NovoCure (NVCR) holds $795.2M in total assets, down 36.2% year over year.
- How much debt does NovoCure have?
- NovoCure carries $37.5M in total debt against $338.1M of shareholders' equity, a debt-to-equity ratio of 0.11.
- How much cash does NovoCure have?
- NovoCure holds $93.7M in cash and equivalents.
- Can NovoCure cover its short-term obligations?
- Its current ratio is 2.89 — current assets exceed current liabilities.
- Where does NovoCure's balance sheet data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
